GW's Epidiolex Clinical Trial Results Summarized in House Oversight Document

GW's Epidiolex Clinical Trial Results Summarized in House Oversight Document The passage provides detailed efficacy data for a FDA‑approved cannabinoid drug but contains no references to influential political figures, intelligence agencies, foreign leaders, or financial misconduct. It is largely a technical summary of clinical trial outcomes, offering little investigative value beyond standard pharmaceutical reporting. Key insights: Epidiolex (CBD) showed a 39% median reduction in convulsive seizures vs. 13% for placebo in Dravet syndrome trial.; Phase III data presented at AES 2016 confirmed significant seizure reductions.; No discussion of potential influence from concomitant AEDs such as clobazam.